Objective. This study is designed to (1) determine the perceived quality of care received by patients with head and neck cancer at the end of their lives, in order to (2) better anticipate and improve upon the experiences of future patients.
D espite significant improvements in the treatment of head and neck cancer, it remains a source of considerable morbidity and mortality, as a substantial proportion of patients will succumb to their disease. Because of the unique properties of the disease itself in combination with the organs and tissues affected, functional deficits and symptomatic consequences are particularly difficult to manage. There is a dearth of data that describe the end-of-life experience associated with head and neck cancer and that likewise suggest strategies for improving upon its management.
Conducting research about the dying process is inherently difficult. Prospective studies are limited by the need to remain unobtrusive during what is a difficult time for all involved parties. Moreover, death is not always predictable, making recruitment for research fraught with challenges. Retrospective analyses have been shown to be effective instruments in assessing the end-of-life experience. Focus groups have proven effective in deriving consensuses with regard to patient and family desires and preferences concerning treatment of terminal head and neck cancer. 1 Patient and family-oriented strategies to assess efficacy of palliative and end-of-life care are crucial. 2, 3 In addition, telephone surveys of family members of deceased head and neck cancer patients are feasible and provide valuable data. 4 A recently validated survey instrument has been designed to assess the quality of treatment at the end of life based on the responses of family members of deceased cancer patients. This Veterans Affairs initiative is titled the PROMISE project (Performance Reporting of Outcome Measures to Improve the Standard of care at End-of-life). 3, 5 This group has devised a Family Assessment of Treatment at the End of life (FATE) survey to be administered to families and significant others of deceased veterans. The survey has been validated, with good discriminant validity when compared with a global assessment as well as via subgroup analysis, with strong homogeneity. 6 The FATE survey proves a useful instrument for the assessment of the quality of care provided at the end of patients' lives that is facile, well tolerated, and brief.
The emergence of this valid and powerful survey instrument designed to describe the quality of the end-of-life experience has created an opportunity to better assess related outcomes in head and neck cancer. We used this survey instrument, coupled with a large, prospective database of head and neck cancer patients, to describe the quality of care received by patients with head and neck cancer at the end of their lives, with the goal of better anticipating and improving on the experiences of future patients. We hypothesize that the FATE survey will ably describe the experiences of head and neck cancer patients at the end of life and will suggest specific predictors of better outcomes among this cohort.
Methods

The SPORE Database
The University of Michigan established the Head and Neck Cancer Specialized Program of Research Excellence (SPORE) in 2002 through funding by the National Cancer Institute. This comprehensive, multidisciplinary research program maintains a prospectively collected database, including clinical characteristics, treatments, and outcomes for thousands of patients who have been diagnosed and treated for head and neck cancer at our institution.
Patients and Recruitment
After approval by the University of Michigan Medical School Institutional Review Board (IRB), the SPORE database was accessed for patient recruitment. The families of deceased SPORE patients treated at the University of Michigan for whom contact information was available were recruited by mail. Exclusion criteria included non-English-speaking interviewees, interviewees who reported being unfamiliar with care received during the last month of life, interviewees who did not identify themselves as one of the patient's primary social supports during the last month of life, and interviewees who were not physically present with the deceased at least once during the last week of his or her life.
Survey
A one-time telephone interview was conducted in accordance with the original description of the FATE instrument. The survey, as initially described, included 32 items in 9 domains. The 9 domains (well-being and dignity, information and communication, respect for treatment preferences, emotional and spiritual support, management of symptoms, choice of inpatient facility, care at the time of death, access to services, and access to benefits) each consist of between 1 and 6 individual questions and are independently validated. To ask relevant and targeted questions given our study population, we chose to use the overall FATE score as well as the domain scores for management of symptoms and care at the time of death as our outcome measures.
The FATE survey was scored and analyzed as described in the publication of its validation. 6 To briefly summarize, "best possible" scores were totaled and divided by the number of responses. Overall FATE and domain scores are expressed as a percentage of valid responses for which respondents gave the best possible response. These scores were averaged and reported.
Five of the questions from the original survey were omitted because they related directly to care provided by the Department of Veterans Affairs. Accordingly, 2 questions concerning transportation assistance within the "access to services" domain were omitted, and the 3 questions comprising the postmortem benefits domain were omitted. The only other alteration was a change of wording to 1 question within the "management of symptoms" domain. The initial question concerned whether patients reexperienced the stress and emotions associated with prior combat experience during the last month of life; this was altered to ask more generally about the level of stress experienced by patients during the last month of life. As a result of these changes, our survey included 27 questions within 8 domains. Survey responders were also given the opportunity to make unsolicited comments at the conclusion of the survey, which were recorded verbatim.
Independent Variables
Demographic and clinical data were prospectively collected within a database as part of the SPORE study. These variables were independently verified via chart abstraction, with the survey respondent providing clarification in the event of missing or conflicting information. The following variables were included: gender, age at death, disease status at death (including locoregional recurrence, distant metastasis, mortality during initial treatment, and second primary), smoking status ("any" tobacco use, stratified into current, former, or never), alcohol use (defined as 2 or more drinks weekly, stratified into current, former, or never), primary site, staging status and American Joint Committee on Cancer (AJCC) stage at the time of diagnosis, and all treatments received in the initial, adjuvant, and salvage settings.
Additional clinical information was collected through chart abstraction and verified/clarified with the survey respondents. This included documentation of the location of death, whether or not the patient received inpatient care during the last month of life, the presence/absence of an advanced directive, DNR/ DNI (do not resuscitate/do not intubate) status, any bleeding or respiratory complaints within the last month of life, and whether palliative care consultation were obtained.
Statistical Analysis
We focused our statistical analysis on the factors that could be most easily modified in a way to improve the end-of-life experience. The dependent variables analyzed included the overall FATE score as well as the domain scores for management of symptoms and care at the time of death. The KruskalWallis test was used to perform bivariate analyses to determine if FATE scores were significantly different based on the following independent variables: disease status at death, location of death, palliative care involvement, palliative treatments received, and whether patient experienced bleeding during the last month of life.
Results
Recruitment
A total of 371 deceased patients who were treated at the University of Michigan Health System (UMHS) were identified within the SPORE database, for whom 286 had updated next-of-kin/family contact information and were initially contacted by mail. A total of 58 individuals consented by phone to participate in the study and completed the survey, for an overall response rate of 20%.
FATE Survey Results
The mean overall FATE score was 62. Mean domain scores ranged from 31 (management of symptoms) to 79 (treatment preferences). Means, ranges, and standard deviations for overall scores and their domains are summarized in Table 1 . The mean scores reported in this study were markedly similar to scores reported in the study which validated the survey; these are also reported in Table 1 for comparative reference. Table 2 lists a representative sample of the unsolicited comments offered by the survey respondents. Table 3 summarizes FATE scores organized by demographic and clinical variables. Approximately three-quarters of the population were men, with a mean age of 64 years. Seventynine percent were former or current smokers at the time of death, and approximately half used alcohol regularly. Most patients had advanced stage tumors, with T3 or T4 primaries. Most were treated primarily with chemotherapy and/or radiation, and 43% received surgical salvage. Fifty-five percent had locoregional disease at the time of death, and approximately one-third died with distant metastases. The majority of patients with disease in the head and neck could not be categorized as having purely "local" or "regional" neoplasms due to tumors infiltrating both sites and/or simultaneous masses in both locations; thus, this group was categorized as "locoregional disease." Slightly more than half received palliative treatment, most of which involved chemotherapy with or without radiation therapy.
Patient Characteristics
Approximately one-third of patients died in the hospital; the rest died at home or in an inpatient hospice setting. Palliative care consultation was involved in 69% of the cases, and 90% of decedents had advanced directives; many also had documented DNR orders.
Bivariate Analyses (Table 3)
Overall FATE Scores. There was no difference in overall FATE scores between patients who had locoregional disease and patients who had distant metastasis at time of death (62 vs "I wish we would have known that the chemo was not going to work sooner, so we would not have had to put him through it." "Nothing can prepare you for a carotid blowout. I wish I had more warning that the cancer was back." "The hospital staff was not as attentive with regard to pain control as hospice was." "Communication between the specialists and our primary doctor was awful." "I was very happy that I was allowed to stay with him up until the end." "We greatly appreciated the honesty and compassion of the doctors when they gave us bad news." "Assisting with logistics and other customer services goes a long way for people who are lost and confused for many different reasons." 63; P = .989). Patients who died at the hospital had significantly lower FATE scores than patients who died at home or in hospice (55 vs 67; P = .023). There was not a significant difference in FATE scores dependent on palliative treatments received (P = .110).
Management of Symptoms. Disease status did not have an
effect on the symptom domain (P = .405). Patients dying in the hospital scored lower than their counterparts (P = .026). We did not find any variation in scores between patients who received palliative care consultation and patients who did not (P = .745). Patients who were treated with palliative chemotherapy and/or external radiation therapy (XRT) had higher scores (P = .011) than those without palliative treatment.
Care at the Time of Death. Disease status at the end of life did not affect the care at the time of death domain score (P = .411). Patients dying at the hospital had lower scores than their counterparts (44 vs 80; P < .0001). Patients with palliative care team involvement scored higher than those without palliative care (77 vs 41; P < .0001). Patients who were treated with chemotherapy and/or XRT had higher scores than those who did not receive palliative treatments (P = .017).
Discussion
Palliative Care
End-of-life care in head and neck cancer is complicated by the unique aspects of the disease itself. In general, palliative care with respect to head and neck cancer is similar in design and execution to its general application, with focus on alleviating pain, treating bothersome symptoms, and allowing for patients to live with dignity and respect. 7 Specifically with head and neck cancer, timely management of pain, addressing difficulty swallowing, and maintenance of an adequate airway are to be stressed. 8 The importance of palliative care teams and the utilization of hospice services cannot be overstated. 9, 10 Given the poor prognosis of many advanced tumors, initial treatments, even those with seemingly curative intent, might be considered by some to be palliative. 11 Timon and Reilly 12 estimate that 20% of patients would qualify for palliative care at the time of initial diagnosis, with an average survival of 5 months within this cohort. Our data confirm the importance and impact of palliative care consultation. Although not significantly affecting the overall FATE score, their involvement in inpatient, outpatient, and hospice settings was associated with higher domain scores with regard to symptom control and care at the time of death. This confirms prior findings of the FATE survey. 5 It is important to note that palliative care involvement need not immediately precede death; in cases in which symptoms are not being effectively managed, when social factors significantly affect care, or in many other situations, palliative care may be helpful, even when death is not imminent. The stigma of palliative care involvement as "giving up" should be replaced with a positive movement toward better control of symptoms and facilitating a proactive role among patients and families. Moreover, opportunities for patients to implement advanced directives and surrogate decision makers can increase the likelihood that their wishes are respected. 13 
Treatments in the Palliative Setting
We were surprised to find that disease status at the time of death did not influence FATE scores. Because of the consequences of locoregional disease on function and symptoms, we postulated that these patients would have lower scores than those succumbing of distant metastasis; this was incorrect. These findings are in need of further study, with use of multiple measures of quality of life and end-of-life experiences and adequate control for potential confounders. That said, obtaining locoregional control in the face of incurable disease must be carefully considered, particularly when treatments themselves are morbid. Our data corroborate the utility of palliative chemotherapy and radiation therapy. Although a survival benefit is important in its own right, our data suggest that these treatments may improve the quality of patients' lives. The optimal regimen of palliative radiation therapy that balances efficacy with limited toxicity remains undetermined; the FATE survey could be used in future such efforts.
14 Other studies investigating the impact of palliative chemotherapy in this population have found that only certain aspects of quality of life improve with such treatments; our data add a new dimension to these preliminary efforts. 15 These findings deserve more rigorous study to be substantiated, and we plan to use the FATE survey in prospective trials assessing the utility and effectiveness of various palliative treatments.
A Multidisciplinary Approach
Reports suggest that patients with head and neck cancer may not receive optimal care at the end of their lives. In 1 study, only 22% of patients had family members present at the time of death, and 35% did not have code status documented. 16 Because of the multidisciplinary nature of care, it is critical to ensure that all involved parties communicate effectively. One survey of primary care providers caring for end-stage head and neck cancer patients revealed that only 33% felt comfortable with their management, and a minority believed that symptom control was adequate. 17 In our study, the information and communication domain score was similar to that found in prior FATE surveys.
The importance of collaboration between patients, families, and caregivers is vital in facilitating discharge from the hospital, as we found this to be one of the most important predictors of better FATE scores. Further research is required, as demographic and cultural factors significantly influence trends and preferences regarding the location of death. 18 Moreover, many of the comments provided by survey responders specifically addressed the need for good communication and illustrated significant problems when deficiencies arose.
Strengths and Weaknesses
This study applied a validated and powerful survey instrument to a population of deceased head and neck cancer patients' families for whom clinical data were accrued prospectively. To our knowledge, this is the first attempt of its kind to quantify and describe the end-of-life experience of head and neck cancer patients in a study with methodological rigor. The use of a prospectively enrolled sample of patients with prospectively collected demographic, clinical, and outcome data strengthens the weight of the analysis by limiting selection bias.
The relatively poor response rate is a weakness of our study and compares unfavorably with that achieved in prior studies using this survey. We attribute this finding to the recruitment process itself; our institution's IRB did not allow us to initiate contact with potential respondents by phone; moreover, participants were not financially compensated, as they were in prior publications of the FATE survey. Despite this limitation, our study population was of sufficient size and diversity to facilitate statistical analyses. We limited the dependent variables to the overall FATE score and 2 domain scores, with a small number of independent variables in an effort to reduce the possibility of type I and II errors.
The retrospective, survey-based nature of the FATE instrument makes controlling for bias problematic. That said, in the survey's original validation, the FATE score was not associated with the respondent's relationship to the patient, frequency of the respondent's contact with the patient in the last month of life, or the elapsed time between death and the interview. 6 Controlling for social status and cultural influences, among other variables that may influence respondents' answers, is difficult. We recognize that the end-of-life experience is quite varied and that multiple confounders may exist, but in our opinion, the use of a validated instrument, coupled with a satisfactory sample size, facilitates a valid analysis.
Another weakness of our study is the different environment in which it was used; prior validation occurred within the Veterans Administration system. To administer the survey to our patient population, 5 questions were eliminated and 1 question was slightly altered from the published, validated survey. We contend that this does not diminish the strength of our conclusions due to the design and scoring of the survey itself, in which questions that were either not applicable or unanswered were simply omitted from the data analysis. The applicability and transmissibility of the study are confirmed by the remarkable association between our overall and domain scores when compared with the prior implementation of the survey.
Conclusion
The FATE survey is a useful measure of the end-of-life experience of head and neck cancer patients. Palliative treatments of head and neck cancer, death outside of the hospital, and palliative care team involvement were associated with significantly improved scores measuring the end-of-life experience in this population. It stands to reason that evidence-based changes in care paradigms modeled on these findings may benefit future patients. This study, with its utilization of a validated survey instrument, coupled with a large, prospectively collected database of head and neck cancer patients, facilitated a concrete and valid analysis of the end-of-life experience of head and neck cancer patients.
